BWS
IBRX icon

Buck Wealth Strategies’s ImmunityBio IBRX Stock Holding History

Buck Wealth Strategies’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$937 Buy
+107
New +$810 ﹤0.01% 942

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.36B AUM 18.79% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 14.43% 1-Year Est. Return
KA
Kercheville Advisors San Antonio, Texas $328M AUM 76.85% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Buck Wealth Strategies's IBRX Position: Q2 2026 in Review

Buck Wealth Strategies opened a new position in ImmunityBio (IBRX) in Q2 2026: 107 shares worth $937. The stake represents ﹤0.01% of the portfolio and ranks #942 among its holdings.

219 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Buck Wealth Strategies held 107 shares of ImmunityBio worth $937 as of Q2 2026.
  • ImmunityBio was a new Buck Wealth Strategies position in Q2 2026.
  • ImmunityBio made up ﹤0.01% of Buck Wealth Strategies's portfolio in Q2 2026, its #942 holding.
  • 219 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Buck Wealth Strategies's 13F filing for Q2 2026, filed 30 Jul 2026.